lymphoid cells

[Immunity] The composition of the intestinal microbiota is associated with both the development of tumors and the efficacy of anti-tumor immunity. Researchers examined the impact of microbiota-specific T cells in anti-colorectal cancer immunity.

[Oncotelic Therapeutics, Inc.] Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.

[G1 Therapeutics, Inc.] G1 Therapeutics, Inc. announced that the company has initiated a Phase II, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response.

[Science Advances] To probe the role of B cells in biomaterial scaffold response, scientists evaluated the B cell response to biomaterial materials implanted in a muscle wound using a biological ECM as a reference for a naturally derived material, and synthetic polyester polycaprolactone as a reference for a synthetic material.

[Cell Stem Cell] The authors reported an analysis on one year of data from the first cohort of 15 patients from a single trial site that received subcutaneous implantation of cell products combined with an immunosuppressive regimen.

[Nature Communications] Investigators found that the core microRNA biogenesis and targeting machinery maintained the sensitivity of cancer cells to PD-1-independent T cell-mediated cytotoxicity.